– USA, TX – Shattuck Labs, Inc. (NASDAQ: STTK) today announced the appointment of Dr. Carrie Brownstein (M.D.), to its Board of Directors, replacing founder and Chairman, Josiah Hornblower who is stepping down from the Board.
Concurrently, Dr. George Golumbeski (Ph.D.) has been appointed the new Chairman of the Board.
“Dr. Brownstein will be a tremendous asset to the Shattuck board, as a seasoned industry veteran with a proven track record of leadership and expertise in strategy and tactical implementation from drug candidate selection through commercialization,” said CEO, Dr. Taylor Schreiber. “She is joining us at a key time in our pipeline progression. Carrie’s clinical development experience will be invaluable as we advance SL-172154 toward later-stage clinical trials and new ARC programs enter the clinic.”
“Now, Shattuck is entering a very exciting time as the company advances its ARC product candidates into later-stage clinical development. I am excited to offer my experience to the company through this next phase of growth as Chairman of the Board,” said Board Chairman, Dr. George Golumbeski.
About Dr. Carrie Brownstein
Dr. Brownstein is the Chief Medical Officer of Cellectis, where she is responsible for overseeing clinical research and development. Previously, Dr. Brownstein held several senior leadership positions, including VP of Global Clinical Research and Development, Therapeutic Area Head for Myeloid Diseases at Celgene, Executive Director of Clinical Sciences Oncology at Regeneron Pharmaceuticals, and Senior Medical Director of Hematology and Oncology at Hoffman-La Roche (Roche Pharmaceuticals). Before her industry career, Dr. Brownstein practiced pediatric hematology and oncology at New York Presbyterian Columbia University and Mount Sinai Medical Center and completed her internship and residency at Columbia Presbyterian Medical Center in New York and her subspecialty training at Memorial Sloan-Kettering Cancer Center.
“I am incredibly excited to join the Board of Directors at Shattuck,” said Dr. Brownstein. “I look forward to working with their experienced and talented management team to further their pioneering work in the exciting area of bi-functional fusion proteins and bring these innovative product candidates through clinical trials to help improve the lives of patients in need.”
Dr. Brownstein received her M.D. from Tufts University School of Medicine and received her A.B. in Psychology from the University of Michigan.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly-owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas, and Durham, North Carolina.
For more information: https://www.shattucklabs.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
